Applications of N-Acetyl-3-Fluoro-DL-Phenylalanine in Industrial Manufacturing

N-Acetyl-3-Fluoro-DL-Phenylalanine supports specialized manufacturing in fine chemical synthesis, high-purity pharmaceutical intermediates, advanced peptide production, and research-grade reference standards. As a direct chemical manufacturer, we ensure product integrity for each downstream sector, attending to compliance, formulation requirements, process integration, and final end use. The following sections outline validated industry uses and technical details that guide production benefit and regulatory alignment.

1. Active Pharmaceutical Ingredient (API) Intermediate for Anticancer Drug Synthesis

Pharmaceutical manufacturers incorporate N-Acetyl-3-Fluoro-DL-Phenylalanine as a selective intermediate during multistep synthesis of targeted anticancer agents. The fluoro-modified amino acid structure enables efficient coupling in solid-phase peptide synthesis, supporting drug candidates in kinase inhibitor and immunotherapy programs. Bulk lots meet ICH Q7 GMP guidance and stringent impurity limits for critical API production. Downstream process control requires analytical release testing by HPLC and chiral purity validation due to its integration at specific elongation stages. API producers adjust loading ratios depending on the target compound's fluorination requirement, leveraging the raw material’s stability and reactivity.

Industry compliance standards

• ICH Q7 and Q11 (Good Manufacturing Practice for APIs)
• USP <823> (Radiopharmaceuticals, if radiolabeling is relevant)
• 21 CFR Part 210/211 (Pharmaceutical cGMP for Finished Drugs)
• ISO 9001:2015 Quality Management System

Typical usage ratio

• 5–20 mol% of protected fluoro-phenylalanine precursors per total amino acid sequence, tailored to the moiety incorporation in small-molecule or peptide drugs

Downstream process integration

• Loaded as a protected amino acid monomer in automated solid-phase peptide synthesis (SPPS)
• Used during resin charging before deprotection/coupling cycles
• Direct manual feeding for solution-phase synthesis when structure-specific fluorination is needed
• Cleavage and purification steps include HPLC and LC-MS for process monitoring

Final product types

• Anticancer peptide APIs (e.g., protease-resistant fluorinated analogs)
• Small-molecule kinase inhibitors
• Radio-labeled diagnostics for oncology applications
• Immunotherapy drug candidates

2. Building Block for Peptide Therapeutic Discovery Platforms

Biotechnology companies source this specialty amino acid to develop proprietary peptide discovery libraries, adding conformational and metabolic stability via fluorine substitution. During lead optimization, medicinal chemists incorporate the compound in combinatorial synthesis to evaluate target engagement and in vivo profiles. Laboratory-scale and pilot plant batches undergo batch records review and analytical substantiation, conforming to chemical supply documentation needed for preclinical R&D and IND-enabling studies. The combinatorial approach determines incorporation quantity, with process variation based on peptide sequence complexity.

Industry compliance standards

• GLP (Good Laboratory Practice) for nonclinical research batches
• ISO 13485:2016 (Medical devices–applicable to peptide diagnostics)
• FDA IND CMC guidance, Section 3.2.S.2.3 (Synthetic Process Description)
• REACH Registration for laboratory chemical usage in EU markets

Typical usage ratio

• 1–3 residues per 20–40mer screening peptide, depending on structural integration strategy

Downstream process integration

• Introduced during combinatorial peptide synthesis cycles in split-and-mix library generation
• Used for analog substitution in high-throughput lead optimization workflows
• Fed into semi-automated purification arrays (RP-HPLC, flash chromatography)
• QC release by mass spectrometry for confirmatory identification

Final product types

• Peptide discovery libraries for target screening
• Structure–activity relationship analogs
• Fluorinated reference peptides for bioanalytical standards
• Non-GMP research-use-only reagents

3. Chiral Sourcing for Stereoselective Organic Synthesis in Fine Chemical Production

Producers of chiral fine chemicals employ N-Acetyl-3-Fluoro-DL-Phenylalanine to introduce defined fluorine chirality in asymmetric synthesis routes. The raw material supports the preparation of high-value, enantioenriched intermediates, where the N-acetyl and fluoro substituents facilitate subsequent functional group transformation. Precise mole ratio selection ensures downstream control during chiral resolution or enantioselective catalysis. Operators implement rigorous in-process controls per ISO and chemical safety standards, with batch traceability and specification conformity required for export and cGMP precursor supply.

Industry compliance standards

• ISO 9001:2015 (Quality Management for Fine Chemical Production)
• OECD Guidelines for the Testing of Chemicals, Section 1 (Chiral Chemicals)
• CLP Regulation (EC) No 1272/2008 (Chemical Labeling and Packaging)
• Responsible Care Global Charter

Typical usage ratio

• 0.5–1.5 equiv per target chiral center, tuned per transformation and catalyst system

Downstream process integration

• Loaded into reactor before asymmetric hydrogenation or resolution step
• Input material for enantioselective biotransformations
• Utilized in Grignard, reduction, or substitution sequences to introduce fluorinated motifs
• Product isolation via crystallization or preparative chromatography

Final product types

• Advanced chiral pharmaceutical/key intermediates
• Enantioenriched fluorinated building blocks
• Amino alcohols for specialty agrochemicals
• Stereo-defined ligands/catalysts for further synthesis

4. Analytical Standard for Quality Control in Pharmaceutical Testing

Regulatory compliance laboratories and pharmaceutical analytical departments use the material as a certified reference standard for chromatographic assay development, stability studies, and impurity profiling of finished drug products. As an authentic lot-manufacturer, we provide traceable COAs, batch-specific purity certification, and documentation for regulatory filings. Users adopt validated HPLC and LC-MS protocols, calibrating detectors against our high-purity standard for system suitability tests and reference peak identification. Laboratories strictly control solution concentrations, diluting stock to match acceptance ranges for professional testing.

Industry compliance standards

• USP <621> (Chromatography)
• Ph. Eur. 2.2.46 (Chromatographic Separation Techniques)
• ISO/IEC 17025 (Testing and Calibration Laboratories)
• FDA 21 CFR 211.194 (Analytical Records)

Typical usage ratio

• 0.005–0.05 mg/mL in mobile phase or sample preparation buffer, based on instrument calibration requirements

Downstream process integration

• Dissolved in suitable solvent system before analytical run
• Injected as external or internal standard in validated HPLC/LC-MS assays
• Storage and dilution managed under controlled temperature and documentation order
• Reference peak assignment for quantitative batch release and stability monitoring

Final product types

• Chemical reference standards for QC labs
• USP/Ph. Eur. certified comparative standards
• Calibration solutions for pharmaceutical release specifications
• Internal controls for impurity testing and method validation